LASA6.82

Lasa Supergenerics Limited

· Pharma & Health
₹ CrorePeersMANGALAMBIOFILCHEMORTINGLOBEVINEETLABKREBSBIOALPABALPHARMANATCAPSUQMcap ₹34.2 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
LASA
FY26
MANGALAM
FY26
BIOFILCHEM
FY26
ORTINGLOBE
FY26
Peer
Median
Valuation — at last close
P/E21.05×21.05×
P/B0.69×0.54×2.72×10.72×2.72× -75%
EV/EBITDA-1.54×-10.74×94.77×-13.19×-10.74× +86%
Market Cap₹34.2 Cr₹55.2 Cr₹58.6 Cr₹13.3 Cr₹55.2 Cr -38%
Growth
Revenue CAGR 3Y-42.11%-1.85%-74.44%-38.14% -10%
Revenue CAGR 5Y-34.11%-4.50%-58.50%-31.50% -8%
Net Income CAGR 3Y70.67%70.67%
Revenue YoY (latest Q)-93.87%-0.40%91.99%-70.85%-0.40% -23368%
Net Income YoY (latest Q)83.05%44.64%-95.47%-92.65%-92.65% +190%
Profitability
EBITDA Margin-112.98%-6.42%2.29%-1030.05%-6.42% -1660%
Net Income Margin-135.60%-19.13%9.81%-736.72%-19.13% -609%
Return on Common Equity-68.70%-43.08%12.92%-59.85%-43.08% -59%
Return on Capital Employed-69.54%-27.98%1.70%-46.19%-27.98% -149%
Return on Assets-51.44%-14.10%6.50%-15.93%-14.10% -265%
Credit & Quality
Total Debt/Equity0.20×1.02×0.14×0.81×0.81× -75%
Interest Coverage-89.13×-2.04×37.37×-470.77×-2.04× -4269%
Scale — latest FY
Revenue / Total Income₹25.1 Cr₹232 Cr₹28.4 Cr₹0.1 Cr₹28.4 Cr -11%
Net Income−₹34.1 Cr−₹44.4 Cr₹2.8 Cr−₹0.7 Cr−₹0.7 Cr -4504%
Total Assets₹66.3 Cr₹315 Cr₹42.8 Cr₹4.6 Cr₹42.8 Cr +55%
EPS₹-6.8₹-28.05₹1.71₹-0.91₹-0.91 -647%
Book Value per Share₹9.9₹65.11₹13.25₹1.52₹13.25 -25%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.